8-K: Bristol Myers Squibb Reports Mixed Q2 2025 Results Amid Strategic Portfolio Shift and BioNTech Partnership

Bristol Myers Squibb reported a 1% increase in second-quarter revenues to $12.3 billion, driven by strong growth in its Growth Portfolio, while updating its full-year 2025 non-GAAP EPS guidance lower due to a significant acquired IPRD charge.

Summary

• Total revenues for the second quarter of 2025 were $12.3 billion, a 1% increase compared to the same period in 2024, and relatively flat excluding foreign exchange impacts.
• Growth Portfolio revenues increased by 18% (17% Ex-FX) to $6.6 billion, primarily driven by immuno-oncology products like Opdivo, Yervoy, Opdualag, and newer therapies such as Breyanzi, Reblozyl, and Camzyos.
• Legacy Portfolio revenues decreased by 14% (15% Ex-FX) to $5.7 billion, mainly due to expected generic impacts on products like Revlimid, Pomalyst/Imnovid, and Sprycel, as well as U.S. Medicare Part D redesign.
• GAAP diluted EPS was $0.64, a 22% decrease from $0.83 in Q2 2024, while non-GAAP diluted EPS was $1.46, a 29% decrease from $2.07 in Q2 2024.
• Both GAAP and non-GAAP EPS figures include a net unfavorable impact of $(0.57) per share from an Acquired IPRD charge associated with the BioNTech strategic partnership.
• Gross margin decreased to 72.5% on a GAAP basis and 72.6% on a non-GAAP basis, primarily due to product mix.
• Selling, general and administrative expenses decreased by 11% (GAAP) and 12% (non-GAAP) to $1.7 billion, driven by strategic productivity initiatives.
• Research and development expenses decreased by 11% (GAAP) to $2.6 billion, primarily due to lower IPRD impairment charges, while non-GAAP R&D decreased 1% to $2.3 billion.
• The company increased its full-year 2025 revenue guidance to a range of ~$46.5 billion to $47.5 billion, up from ~$45.8 billion to $46.8 billion.
• Full-year 2025 non-GAAP EPS guidance was updated to a range of $6.35 to $6.65, down from $6.70 to $7.00, reflecting the $(0.57) per share impact from the BioNTech Acquired IPRD charge.
• Net debt position improved to $(35.2) billion as of June 30, 2025, from $(38.5) billion as of December 31, 2024.
• Cash flow from operations for Q2 2025 was $3.9 billion.

Sentiment

Score: 7

Explanation: The company is undergoing a significant portfolio transition, with strong growth in new products offsetting declines in legacy ones. Strategic business development activities are robust, and debt reduction is on track. While EPS was impacted by a large IPRD charge, this is a strategic investment for future growth. The raised revenue guidance indicates underlying operational strength. The Reblozyl trial miss is a setback, but overall, the company is executing its long-term growth strategy.

Positives

• Growth Portfolio revenues increased by 18% to $6.6 billion, demonstrating strong performance from newer products.
• Opdivo sales grew 7% worldwide to $2.56 billion, with strong demand and successful launch in 1L MSI-high colorectal cancer.
• Reblozyl sales increased 34% worldwide to $568 million, driven by continued demand in 1L MDS-associated anemia and new launches in Europe and Japan.
• Breyanzi sales surged 125% worldwide to $344 million, establishing it as the #1 CAR T in the U.S. with strong demand across all indications.
• Camzyos sales grew 87% worldwide to $260 million, reflecting strong U.S. demand in obstructive hypertrophic cardiomyopathy (oHCM).
• Sotyktu sales increased 31% worldwide to $70 million, benefiting from U.S. access improvements and new market launches internationally.
• Full-year 2025 revenue guidance was raised to $46.5 billion $47.5 billion, reflecting Growth Portfolio strength and better-than-expected Legacy Portfolio sales.
• Strategic partnership with BioNTech for global co-development and co-commercialization of bispecific antibody BNT327 enhances the oncology pipeline.
• RayzeBio (a BMS company) licensed exclusive worldwide rights to OncoACP3, strengthening its position in radiopharmaceuticals for prostate cancer.
• Formation of a new, independent biopharmaceutical company with Bain Capital, focused on autoimmune diseases, with a $300 million financing commitment.
• FDA approved label updates for CAR T cell therapies Breyanzi and Abecma, reducing patient monitoring requirements and removing REMS programs.
• European Commission approved a new subcutaneous formulation of Opdivo, offering treatment efficiencies.
• The company is on track to pay down approximately $10 billion of debt by the end of Q2 2026, having achieved approximately $6.5 billion as of Q2 2025.
• A new direct-to-patient option for purchasing Eliquis was announced, aiming to lower out-of-pocket costs for uninsured/underinsured patients.

Negatives

• Legacy Portfolio revenues decreased by 14% to $5.7 billion, primarily due to generic competition and Medicare Part D redesign.
• Revlimid sales declined 38% worldwide to $838 million due to generic impacts.
• Pomalyst/Imnovid sales decreased 26% worldwide to $708 million, impacted by generic entry in the EU.
• Sprycel sales plummeted 72% worldwide to $120 million following the U.S. generic launch.
• GAAP EPS decreased 22% to $0.64, and non-GAAP EPS decreased 29% to $1.46, largely due to a significant Acquired IPRD charge.
• The Phase 3 INDEPENDENCE trial for Reblozyl in myelofibrosis-associated anemia did not meet its primary endpoint of RBC transfusion independence.
• Full-year 2025 non-GAAP EPS guidance was lowered to $6.35 $6.65, inclusive of the unfavorable $(0.57) per share BioNTech Acquired IPRD charge.
• Gross margin decreased on both GAAP and non-GAAP bases, primarily due to product mix.

Risks

• Increasing pricing pressures from market access, pharmaceutical pricing controls, and discounting.
• Market actions by private and government payers to manage drug utilization and contain costs.
• Government actions relating to the imposition of new tariffs, trade restrictions, and export regulations.
• Ability to retain patent and market exclusivity for certain products.
• Regulatory changes that result in lower prices, lower reimbursement rates, and smaller populations for whom payers will reimburse.
• Changes under the 340B Drug Pricing Program.
• Ability to obtain and maintain regulatory approval for product candidates.
• Difficulties and delays in product introduction and commercialization.
• Increasing industry competition.
• Potential difficulties, delays, and disruptions in manufacturing, distribution, or sale of products.
• Ability to identify potential strategic acquisitions, licensing opportunities, or other beneficial transactions.
• Failure to complete, or delays in completing, collaborations, acquisitions, divestitures, alliances, and other portfolio actions and the failure to achieve anticipated benefits from such transactions and actions.
• Exposure to litigation and/or regulatory actions or investigations.
• Impact of any healthcare reform and legislation or regulatory action in the United States and international markets.
• Increasing market penetration of lower-priced generic products.
• Failure of suppliers, vendors, outsourcing partners, alliance partners, and other third parties to meet their contractual, regulatory, and other obligations.
• Impact of counterfeit or unregistered versions of products and from stolen products.
• Product label changes or other measures that could result in declining sales.
• Safety or efficacy concerns regarding products or any product in the same class.
• Risk of cyber-attacks and unauthorized disclosure of trade secrets or other confidential data.
• Ability to execute financial, strategic, and operational plans.
• Ability to attract and retain key personnel.
• Impact of significant indebtedness.
• Political and financial instability of international economies and sovereign risk.
• Interest rate and currency exchange rate fluctuations, credit and foreign exchange risk management.
• Risks relating to the use of social media platforms.
• Issuance of new or revised accounting standards.
• Risks relating to public health outbreaks, epidemics, and pandemics.

Future Outlook

The company is raising its full-year 2025 revenue guidance to a range of ~$46.5 billion to $47.5 billion, reflecting the strength of its Growth Portfolio, better-than-expected Legacy Portfolio sales in Q2, and a favorable foreign exchange impact. Non-GAAP EPS guidance is updated to $6.35 to $6.65, which includes an unfavorable $(0.57) per share impact from the BioNTech Acquired IPRD charge. Operating expenses are expected to be approximately $16.5 billion, reflecting investments in business development and the Growth Portfolio. The company anticipates higher royalties and favorable interest income contributing to approximately $250 million in other income and expense.

Management Comments

• "We are making good progress rewiring the company for long-term growth. In the second quarter, we delivered strong results across our Growth Portfolio, continued to optimize our cost structure, and added to our innovative pipeline with strategic partnerships." Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Squibb.
• "In the back half of the year, we're focused on advancing transformational medicines and delivering on our Growth Portfolio and important pipeline opportunities to shape our growth trajectory." Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Squibb.

Industry Context

Bristol Myers Squibb's Q2 2025 results reflect a broader industry trend of pharmaceutical companies navigating patent expirations and generic competition for older, high-revenue drugs by investing heavily in new, innovative therapies and strategic partnerships. The significant growth in the 'Growth Portfolio' driven by oncology and immunology assets, coupled with strategic business development activities like the BioNTech collaboration and the formation of an immunology-focused NewCo, demonstrates a clear pivot towards high-growth, specialized therapeutic areas. This strategy aims to offset the anticipated revenue decline from 'Legacy Portfolio' products facing generic erosion and evolving healthcare policies like Medicare Part D redesign, positioning the company for future growth in a competitive and evolving pharmaceutical landscape.

Comparison to Industry Standards

• The 18% growth in the Growth Portfolio (17% Ex-FX) is strong, particularly for a large pharmaceutical company, indicating successful commercialization of newer assets like Breyanzi (+125%) and Camzyos (+87%). This outpaces typical single-digit growth rates seen in mature pharmaceutical segments.
• The decline in Legacy Portfolio revenues, particularly Revlimid (-38%) and Sprycel (-72%) due to generic entry, is a common challenge for pharmaceutical companies facing patent cliffs, comparable to situations faced by companies like Teva Pharmaceuticals or Mylan (now Viatris) when major drugs lose exclusivity.
• The strategic partnership with BioNTech for a bispecific antibody (BNT327) aligns with industry trends where large pharma companies collaborate with biotech innovators to expand their oncology pipelines, similar to partnerships seen between Merck and Moderna, or Pfizer and BioNTech itself for vaccine development.
• The formation of an independent immunology biopharmaceutical company with Bain Capital is an innovative approach to externalize and optimize specific assets, a strategy increasingly adopted by large pharma (e.g., Novartis's spin-off of Sandoz) to unlock value and focus on core areas, while leveraging external capital and expertise.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through strategic portfolio shift and pipeline expansion, but near-term EPS dilution due to IPRD charges and ongoing generic erosion of legacy products.
• Patients: Continued development and commercialization of innovative medicines, including new formulations and expanded indications for existing therapies, and efforts to improve access to drugs like Eliquis.
• Employees: Ongoing strategic productivity initiatives may imply workforce adjustments, while new business development activities could create new opportunities.
• Customers (Healthcare Providers): New product approvals and formulations offer additional treatment options and potentially improved administration methods.
• Creditors: Commitment to maintaining an investment-grade credit rating and significant debt reduction efforts enhance financial stability.

Next Steps

• Engage with the FDA and EMA to discuss the submission of marketing applications for Reblozyl despite the Phase 3 INDEPENDENCE trial not meeting its primary endpoint.
• Close the definitive agreement between RayzeBio and Philochem AG for the exclusive worldwide rights to OncoACP3, expected in the third quarter of 2025.
• Advance transformational medicines and deliver on Growth Portfolio and pipeline opportunities in the second half of 2025.
• Continue to execute on the strategic productivity initiative to optimize cost structure.
• Monitor and report on key pipeline milestones, including upcoming data readouts for various assets in 2025, 2026, and 2027.

Key Dates

Recommendation

The company is in a transitional phase, successfully growing its 'Growth Portfolio' and executing strategic business development deals that promise long-term value. However, this comes at the cost of significant near-term EPS dilution due to IPRD charges and continued revenue decline from 'Legacy Portfolio' products facing generic competition. The mixed Q2 results and updated guidance reflect these dynamics. A 'hold' recommendation is appropriate as investors await further clarity on the successful integration and commercialization of new assets and the full impact of the strategic shifts, balancing the long-term potential against near-term headwinds and execution risks.

Keywords

Pharmaceuticals, Biotechnology, Oncology, Immunology, Cardiovascular, Hematology, Drug Development, Clinical Trials, SEC Filing, Earnings Report, Guidance, Strategic Partnerships, Acquired IPRD, Generic Competition, Pipeline, CAR T, Eliquis, Opdivo, Revlimid, Breyanzi, Reblozyl, Camzyos, Sotyktu